Clinical effect and safety of gefitinib and erlotinib second line treatment of lung adenocarcinoma
10.13699/j.cnki.1001-6821.2015.11.001
- VernacularTitle:吉非替尼与厄洛替尼二线治疗晚期肺腺癌的临床疗效及安全性
- Author:
Ya-Jun ZHANG
1
;
Hong-Bing LI
;
Xian-Dong LI
;
Xiao-Chun LIU
;
Ji-Chang HAN
Author Information
1. 河南大学 淮河医院 呼吸科
- Keywords:
lung adenocarcinoma;
gefitinib;
erlotinib;
adverse drug reaction
- From:
The Chinese Journal of Clinical Pharmacology
2015;(11):899-901
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects and safety of gefitinib ver-sus erlotinib second line treatment of lung adenocarcinoma.Methods Eight six pathology confirmed lung adenocarcinoma were included in this study.Patients in the gefitinib group were administered of gefitinib 250 mg orally per day until disease progression.Patients in the erlotinib group were given erlotinib150 mg orally per day until disease progression.The clinical activity such as objective response rate, median survival and toxicity were compared between the two groups.Results The objective response rate were 24.3%and 26.7%for the gefitinib group and erloti-nib group respectively with no statistical difference(P>0.05).The medi-an survival time were 13.5 months and 13.2 months in the gefitinib group and erlotinib group respectively with no statistical difference ( P>0.05 ).The main drug related toxicity were rash and diarrhea for the two groups with no significant difference ( P >0.05 ).Conclusion Gefitinib and erlotinib were similar in the aspects of efficacy and drug related adverse events for the second line treatment of lung adenocarcinoma.
